InnoCan Pharma Corporation (CSE:INNO) (OTCMKTS:INNPF) (FRA:IP4) reported the successful completion of a large-scale production of exosomes as part of its CBD Loaded Exosome (CLX) Therapy project in collaboration with Professor Daniel Offen of Tel Aviv University.
The company said it considers CLX to be a new revolutionary, development-stage, cell therapy-based technology, loaded with CBD (cannabidiol), designed to target coronavirus infected lung cells and central nervous system diseases, with the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells.
InnoCan Pharma described the product as acting as a “guided missile,” bringing the combination of the cell healing properties of exosomes and the anti-inflammatory properties of CBD to the infected lungs.
“Innocan is now one of a few public companies in the exosome's science field,” CEO Iris Bincovich said in a statement.
She added: “Although we are still in the development stage of the CLX platform, large scale exosome production capabilities are a significant proof of advantage and capability for Innocan, as part of the path to commercialization.”
Professor Daniel Offen also weighed in on the achievement, stating: “To demonstrate the ability of a semi-commercial exosome production from a human cell source which can serve as the source of the CLX platform is a key milestone at the development stages.”
He added: “Now, when we know we can produce exosomes in large quantities we can concentrate on the CBD loading technologies and examine different potential indications for the use of the CLX Therapy.”
Innocan noted that it managed to perform the production of trillions of exosomes, which are released by regenerative cells that drive the healing and repair process, in a short period of time in a 3-dimensional bioreactor.
It added that the achievement may lead to economic large scale exosome production for the CLX, which is expected to pave the way for larger tests and studies.
Innocan also said the project demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process.
Contact Sean at email@example.com